Express News | Chengda Pharmaceutical: Qianhai Shengtai plans to reduce its stake by no more than 4.89%.

BreakingsMay 11 19:09

Express News | The healthcare services sector in China's A-share market strengthened at the opening of trading. Wuxi Apptec surged over 9% following its earnings release, while Chengda Pharmaceuticals rose more than 4%. Other stocks such as Kanglong Huacheng, BioRay Bio

BreakingsApr 28 09:29

Chengda Pharmaceutical: 2025 Annual Report

SZSIApr 28 00:00 · Announcements

Chengda Pharmaceutical: First Quarter Report for 2026

SZSIApr 28 00:00 · Announcements

Chengda Pharmaceutical: Summary of the 2025 Annual Report

SZSIApr 28 00:00 · Announcements

Chengda Pharmaceutical (301201.SZ): Achieved a net profit attributable to shareholders of 7.002 million yuan in the first quarter.

Gelonghui, April 27th ─ Chengda Pharmaceutical (301201.SZ) released its Q1 2026 report. During the reporting period, the company achieved revenue of 128 million yuan, representing a year-on-year increase of 68.06%. Net profit attributable to shareholders of the listed company was 7.002 million yuan, while net profit attributable to shareholders excluding non-recurring gains and losses was 3.0986 million yuan. Basic earnings per share were 0.0462 yuan.

Gelonghui FinanceApr 27 18:12